Executive Summary

Investment Thesis: Tempest Therapeutics ($TPST) is a clinical-stage oncology company that just posted an unexpected Q4 EPS beat and acquired dual-CAR T assets (TPST-2003), creating a visible clinical pathway toward a potential U.S. registrational study in 2026. Analysts are broadly positive, with 6 of 7 covering firms rating the stock Strong Buy or Buy, and management says the acquisition extends runway to mid-2027. At the same time the company carries deep historical losses, a collapsed market capitalization of roughly $20 million, and material dilution risk that could impair shareholder value. The stock looks like a high-risk, binary biotech punt rather than a steady growth story.

Current Price: $1.61 | Key Metric: EPS (TTM) $-10.40 | Stance: NEUTRAL

Company Overview

Tempest Therapeutics, Inc. operates in the Biotechnology sector developing oncology therapeutics. The company focuses on small-molecule immuno-oncology programs and, more recently, acquired clinical-stage dual-targeting CAR-T assets intended to diversify and accelerate its pipeline.

Key Products & Competitive Position

Core Business: Clinical-stage oncology R&D, with small molecules and now cell therapy assets.
Key Products: Amezalpat (oral PPAR-alpha antagonist for hepatocellular carcinoma), TPST-1495 (dual EP2/EP4 antagonist), and newly acquired TPST-2003 (CD19/BCMA dual-CAR T program).
Competitive Moat: A collaboration with Roche on Amezalpat and a differentiated dual-target CAR-T strategy could provide clinical differentiation, but the moat is narrow until significant clinical data and regulatory milestones are achieved.

Recent Developments

Notable items include a March 30, 2026 Q4 release showing an EPS of $(0.62) that beat the $(3.52) consensus estimate; closing of an acquisition bringing in dual-CAR T programs labeled TPST-2003; interim REDEEM-1 data updates on TPST-2003 suggesting potential registrational-path planning; and management commentary that the acquisition plus other actions extend runway through mid-2027.

Financial Snapshot

Market Cap$20.0M

P/E RatioN/A (negative EPS)

52-Week Range$1.50 - $12.23

Dividend Yield0.0%

EPS (TTM)$-10.40

ROE-310.89%

Revenue & Earnings Trends

Tempest remains a development-stage biotech with limited product revenue. Q4 2025 delivered an EPS of $(0.62) that materially beat a consensus estimate of $(3.52), suggesting either lower-than-expected operating losses for the quarter or one-time items that reduced the reported loss. Trailing EPS remains deeply negative at $-10.40, so conventional profit multiples are not informative. The company’s revenue base is negligible for valuation by traditional sales multiples.

Balance Sheet Highlights

Current ratio is a healthy 2.30, indicating short-term liquidity above current liabilities. Market capitalization sits at roughly $20 million, which is tiny for a company running multiple clinical programs. Management says the acquisition plus cash preservation measures extend runway into mid-2027, but that timeline is sensitive to R&D spend and potential financing activity. Cash on hand details are not provided in the dataset here, but investors should treat runway claims as contingent on expected milestones and capital markets access.

Valuation Analysis

Current Valuation Metrics

Forward P/EN/Avs Industry: N/A

PEG RatioN/AGrowth-adjusted

EV/EBITDAN/Avs Historical: N/A

P/S RatioN/Avs Peers: N/A

Historical Comparison

TPST’s current share price sits roughly 86.8% below its 52-week high of $12.23. The two-year total return has been deeply negative, roughly -96.9%. Historical valuation metrics are distorted by episodic dilution, trial readouts, and restructurings, so a conventional multiple comparison is of limited use. For clinical-stage biotechs the market prices binary event risk more than steady-state earnings multiples.

Fair Value Estimate

Given the company’s clinical-stage profile and lack of material revenue, a risk-adjusted pipeline valuation is more appropriate than a DCF. Using conservative assumptions for probability of success across Amezalpat and TPST-2003, the presence of a Roche collaboration, and substantial dilution risk, a midpoint fair-value scenario centers near $5.00 per share. That assumes successful interim data for TPST-2003, continued collaboration advancement of Amezalpat, and a modest financing that preserves the development timeline. Outcomes could vary widely; in a bull outcome the asset mix could justify substantially higher values, while clinical or funding setbacks could push the fair value well below $1.00.

Competitive Landscape

Market Position

Market Share: Negligible in commercial oncology markets | Ranking: Early-stage clinical biotech

Key Competitors

$CARVSmaller cell therapy developer with CAR-T focus

$TNGXMid-stage oncology biotech with small molecules and antibody programs

$JUNOEstablished CAR-T player and comparative benchmark for cell therapy development

Competitive Advantages

Moat 1: Roche collaboration on Amezalpat provides validation and potential co-development resources.
Moat 2: Dual-target CAR-T (CD19/BCMA) could offer clinical differentiation in hematologic malignancies if safety and efficacy align.
Moat 3: A diversified pipeline spanning oral small molecules and cell therapy reduces single-asset binary risk, at least in principle.

Earnings Track Record

Last 4 Quarters: 3 beats / 1 misses

Recent Earnings History

Q4 2025$(0.62) vs $(3.52) estBEAT

Q3 2025(reported better than expected)BEAT

Q2 2025(missed estimates)MISS

Q1 2025(beat estimates)BEAT

Guidance Trend

Management has not provided traditional multi-quarter financial guidance. Instead the company gives operational milestones and runway statements, notably projecting runway to mid-2027 following the TPST-2003 acquisition. Investors should expect guidance to be milestone-driven and subject to revision if trial enrollment or financing plans change.

Analyst Sentiment

Consensus Rating: Strong Buy

Strong Buy: 2 Buy: 4 Hold: 1 Sell: 0

Price Targets

Low: $0.50
Mean: $5.00 (+211% upside)
High: $12.00

Recent Analyst Actions

Several analysts increased optimism after the Q4 EPS beat and the TPST-2003 acquisition. The consensus reflects hope that the dual-CAR T program can be advanced rapidly, backed by the Roche collaboration on Amezalpat and the company’s stated runway extension.

Recent News & Catalysts

Key Developments

Q4 EPS Beat (3/30/2026): Reported EPS $(0.62) vs $(3.52) expected, a notable upside that reduced near-term loss expectations.
Acquisition of TPST-2003: Strategic acquisition of dual-CAR T assets aimed at expanding the pipeline and enabling a potential US registrational path in 2026.
Runway Extension: Management projects runway to mid-2027 after acquisition and cost actions, though this is dependent on execution and financing environment.

Upcoming Catalysts

Next Earnings: 2026-05-11 After Market | Key Events: Interim REDEEM-1 data updates, progress updates on TPST-2003, updates from the Roche collaboration, and any financing announcements are items to watch.

Technical Outlook

Current Price: $1.61 vs 52-Week High: $12.23 (-86.8% from high)

Trend Analysis

The share price has collapsed from a 52-week high of $12.23 to the current $1.61, reflecting a deep market reassessment. Trading volume has been episodic around news events. The recent string of positive operational announcements has produced short-term momentum, but the prevailing trend remains down until the stock can break higher on consistent data or financing clarity.

Key Levels

Resistance: $3.00, $6.00
Support: $1.50 (recent low), $1.00

Bull vs Bear Case

Bull Case

Catalyst 1: Positive interim REDEEM-1 data for TPST-2003 leads to a registrational pathway and partnership or buyout interest, accelerating value capture.
Catalyst 2: The Roche collaboration on Amezalpat progresses into a larger randomized global study, validating the small-molecule strategy and derisking that asset.
Catalyst 3: Successful non-dilutive financing or a strategic partner provides runway beyond mid-2027, limiting shareholder dilution and enabling full development plans.

Bull Target: $12.00 (+644%)

Bear Case

Risk 1: Clinical setbacks or safety signals with CAR-T or small-molecule programs reduce the probability of regulatory success and wipe out upside.
Risk 2: Cash burn and the need for frequent financing lead to heavy dilution, pushing per-share value sharply lower despite any clinical progress.
Risk 3: Competition from larger, better-funded immuno-oncology and CAR-T developers squeezes market opportunity and partner interest.

Bear Target: $0.50 (-69%)

Risks to Consider

Valuation Risk: There is no reliable earnings multiple to justify the current price, and fair value hinges on binary clinical outcomes and partnership success.
Competitive Risk: The CAR-T and immuno-oncology spaces are crowded with deep-pocketed competitors, which raises the bar for new entrants and combination strategies.
Macro Risk: Capital markets conditions can sharply impact small-cap biotechs, increasing the cost of capital and the likelihood of dilutive financing.
Execution Risk: Trial enrollment, manufacturing scale for cell therapies, and regulatory interactions could all delay milestones and require additional funding.

Bottom Line

Investment Verdict: NEUTRAL

Tempest Therapeutics presents a polarized risk/reward profile. Data beats and the acquisition of TPST-2003 create clear upside scenarios, and analysts are optimistic. At the same time the company is loss-making with an EPS (TTM) of $-10.40, a market cap of roughly $20 million, and a steep historical share-price decline. You should expect binary moves tied to clinical readouts and financing announcements rather than steady appreciation.

Action Items for Investors

Long-term investors: Monitor clinical milestones, Roche collaboration progress, and cash runway metrics before reassessing exposure to the pipeline. Ask how financing would affect your stake.
Short-term traders: Watch for volatility around the 2026-05-11 earnings date, REDEEM-1 updates, and any financing notices, and size positions for high beta risk.
Risk management: Consider position sizing that reflects potential dilution and binary trial outcomes, and set stop-loss or re-evaluation points tied to milestone slips or unexpected financing terms.

What to Watch This Week

Operational updates on TPST-2003 development and any new interim REDEEM-1 data releases.
Company statements clarifying the cash runway, detailed cash balances, and any planned financings.
Analyst notes or conference presentations that expand on the Roche collaboration and registrational planning.

TPST: Dual-CAR T Acquisition, Clinical Catalysts